黑色素瘤疗法 z-bo 2020-10-28 378

　　A few days ago, in a research report published in the international journal Cancer Immunology Research, scientists at Monash University and other institutions discovered special new markers of HLA-related peptides in the expression of melanoma tumors. It is expected that relevant research results will be useful and researchers are developing new vaccines to prevent melanoma.

　　Scientists have made a lot of research progress in the treatment of melanoma, but due to lack of effective treatment, one Australian melanoma patient dies every five hours. You can pass a new type of treatment. It can recognize small tumor-specific protein fragments (peptides) that decorate the surface of tumor cells, regulate the body's own immune system, and help detect and kill tumor cells. In this article, researchers have successfully identified thousands of special peptides on the surface of melanoma tumors. These peptides are recognized by the host's immune system.

　　Related research results have created rapid clinical application value. Currently, researchers are collaborating on clinical vaccination trials for melanoma patients using spliced peptides. Researcher Woods pointed out that melanoma is closely monitored under different growth conditions. The host's immune system and various melanoma peptides discovered in this study have not been reported in many previous studies. This is really exciting. The results of the study show that some melanoma peptide markers can be produced through the splicing process. In the splicing process, the protein is first cut into small fragments of peptides, and then the two fragments are pasted together to form a "splicing." "Peptides" (splicing peptides) can be synthesized in vitro and injected into patients by identifying specific splicing peptides to identify and target specific tumors in the immune system.

　　The goal of the researchers is to find a target for the development of new melanoma therapies. They did not realize the existence, spread and importance of these special splicing peptides, nor were they recognized by the body's immune system. Researchers have discovered these splicing peptides and hope to use them as food to function the host immune system. Researcher Andreas Behren pointed out that the findings in this article are very exciting for us. This allows you to identify specific melanoma pricing peptide molecules in patients with different immunogenicity. Based on the results of previous studies, the spliced peptide antigen has been deleted from the original immunological research. Not only in melanoma research, but also in other areas of cancer research, curiosity has become a new and operational target. Based on the new workflow developed by the researchers, they can now identify neglected peptide molecules, which may lay a certain foundation for future immunotherapy and the development of new cancer vaccines. In fact, the universality of this splicing process points to a special class of antigens used in infectious diseases and autoimmunity. Both disease and allergic diseases play an important role.